title: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
abstract: BACKGROUND
  Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive T lymphocytes may cause selective immunosuppression. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the alpha chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation.
  
  
  METHODS
  We administered daclizumab (1.0 mg per kilogram of body weight) or placebo intravenously before transplantation and once every other week afterward, for a total of five doses, to 260 patients receiving first cadaveric kidney grafts and immunosuppressive therapy with cyclosporine, azathioprine, and prednisone. The patients were followed at regular intervals for 12 months. The primary end point was the incidence of biopsy-confirmed acute rejection within six months after transplantation.
  
  
  RESULTS
  Of the 126 patients given daclizumab, 28 (22 percent) had biopsy-confirmed episodes of acute rejection, as compared with 47 of the 134 patients (35 percent) who received placebo (P=0.03). Graft survival at 12 months was 95 percent in the daclizumab-treated patients, as compared with 90 percent in the patients given placebo (P=0.08). The patients given daclizumab did not have any adverse reactions to the drug, and at six months, there were no significant differences between the two groups with respect to infectious complications or cancers. The serum half-life of daclizumab was 20 days, and its administration resulted in prolonged saturation of interleukin-2alpha receptors on circulating lymphocytes.
  
  
  CONCLUSIONS
  Daclizumab reduces the frequency of acute rejection in kidney-transplant recipients.
authors.affiliation: University of California, San Francisco 94143-0116, USA.
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: R
authors.initials: R
authors.lastname: Kirkman
authors.forename: S
authors.initials: S
authors.lastname: Light
authors.forename: G
authors.initials: G
authors.lastname: Bumgardner
authors.forename: M
authors.initials: M
authors.lastname: Pescovitz
authors.forename: P
authors.initials: P
authors.lastname: Halloran
authors.forename: J
authors.initials: J
authors.lastname: Neylan
authors.forename: A
authors.initials: A
authors.lastname: Wilkinson
authors.forename: H
authors.initials: H
authors.lastname: Ekberg
authors.forename: R
authors.initials: R
authors.lastname: Gaston
authors.forename: L
authors.initials: L
authors.lastname: Backman
authors.forename: J
authors.initials: J
authors.lastname: Burdick
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004311:Double-Blind Method; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab